{"name":"Aurinia Pharmaceuticals Inc.","slug":"aurinia-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients with autoimmune diseases. The company's lead product, LUPKYNIS, is approved for the treatment of lupus nephritis, and it has several other compounds in various stages of clinical development.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":283055000,"revenueGrowth":267.1,"grossMargin":0,"rdSpend":32505000,"netIncome":287202000,"cash":751587000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"LUPKYNIS","genericName":"LUPKYNIS","slug":"lupkynis","indication":"Lupus nephritis (Class III or IV)","status":"marketed"}]}],"pipeline":[{"name":"LUPKYNIS","genericName":"LUPKYNIS","slug":"lupkynis","phase":"marketed","mechanism":"LUPKYNIS (voclosporin) is a calcineurin inhibitor that suppresses T-cell activation and cytokine production to reduce lupus nephritis inflammation.","indications":["Lupus nephritis (Class III or IV)"],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1OUlJRT2N5RXB3U29lTm9MZ0VwdGNPQjZBdDY2REFYOEtPdXZhMUlWdmV6ZmpiWC1reGZ1NmYxUktnMmxaU2ZWQmxTc29CSVBfREpxbEFMd09SY3dtYWhZ?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"AUPH Stock Price, Quote & Chart | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill","headline":"AUPH Stock Price, Quote & Chart | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxNd2FMT1gwTUZwNldIUklCb0xmUURGc1JtQ2dZYXlaZG1vRzgyTzB5SFhfRVNzNFJzelp0Z0RsSzRIbTEzNlo1WWVZeFlYM2VPOVdaY2ttTWVONWp3OTFhYXg2ZXRES2lLN2c0Z09rV1ozTUNaTWVLQnd1djFZRzhuUG90YmdVSWl1SVJfanQxOVFmQTdoVmdNaHhuZUgxcGtZbnZwa1EwSTBrNGVIdzBLUVBmNFByQ3BEX2VxN0dfdUQ0Z1NoaVhoeFVUQ0lreThjcTIyRWpQZE5FMmpoa0JidVVrQXJ2b1JZNG5wQXQwaEFjcFVaaHl6cTFpbWo0YkpUUmc?oc=5","date":"2026-03-30","type":"deal","source":"Business Wire","summary":"Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Business Wire","headline":"Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPdDgzQU1MbHZwQTA5dmhzSDY3SGhvWFVfd2I0NnBTRHNNTDJ3Wm1aZGo0T3ZfUnlzV1Y0TnVjQ2txNUppdVU3TU5VQ01ycC1Jc3RSRjVKNmIxeDVSaWR3T2VGSUNOQUtRbjVQTUNRN1I0OS1VRUJTTmNtZjFkTUFDa0F2U0tmMmFBVXBrY1AxcWF2UDhvSzlDbXprOGE?oc=5","date":"2026-03-23","type":"pipeline","source":"Business Wire","summary":"Aurinia Announces Management Transition - Business Wire","headline":"Aurinia Announces Management Transition","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxONEk5Q1c3X19maFpYU2MxUzdPaFhTVjNtaVhraHM0MEtUUUh3T2djTjVxdUhVSy1xaGMzbUt0bVlDcjN5TF9UaUNreHZXWTU2R29TYmlwbm8ydlMwS0hwZWhoN1c0UFZiaHBjR0dEOG0tU01ZdDJjSWI1RllUdVRSZkhPRjdyUQ?oc=5","date":"2026-02-28","type":"deal","source":"Insider Monkey","summary":"12 Cheap Biotech Stocks to Buy Now - Insider Monkey","headline":"12 Cheap Biotech Stocks to Buy Now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQdmlya3JJeHF0TE1oT29lcDVZZzlndC0wZ19hU3NLVGtQWndqd0NzQmsxSUlUQlU3MGZiWDE0Rmx5WFNJYlRVMjI0UC1VSklURFlvVjBTRDRkVXB6ZFBIWm1JTUlXb3hJckV2bDFVOVcwMEpTbG14OUVPc2FCRjA0eG0zZ1k3OGs3Tm9BVnpxWjRUdHhMV0tBeU9nY1pyTVE4SllHSGhCMUs2N1BPelVFQUl6Zk01WkVybGdDS1B3RmFwcUZmQVhybTFVUUR1NFU?oc=5","date":"2026-02-26","type":"earnings","source":"Stocktwits","summary":"AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates - Stocktwits","headline":"AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates","sentiment":"negative"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxOenc2MHNIS1FraHJVeTZySzFEbXJNR2d5NnFjeVpwQTQwSEtEVUdKc3Fqd0g2aHBBSkg1czNzc19vdnJNSDhiemhncjhYUHQxY05EeE9qYWx3SEtNa3hCUHF4LUszV0ZKa3dkMXp4ckNiSUQwNTliWVVIRkJmWnB0WU9VUDl0NVc2emJURHVfd1FWelU5ejdyMG14OFQyUmNETk9sNFFCajhsSGg1Tnk1UzlQX1dWUzhHb2xJSldITGNhOHpOOFpLZG1NTWxZbXlIY0hNaHBOeDg1cURWWnNBNkdhSDVWQUQzSVVtdkk1dHNwcVhRdVZYZ2UxV3dwUDZVaGJvNDRGSUs1U3RVNDVhbjFJdS1oR2pJRWhLZU5jd0htYXM1Q0picGppa1hCU1VzWENrUEVJTUdZMFdubjU1cWl2NTJYaWthaF9jY1ozVQ?oc=5","date":"2026-02-19","type":"pipeline","source":"Business Wire","summary":"Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026 - Business Wire","headline":"Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNcGxnc2JvQjNTUGx6VG01MlRZOG5fU2NrejlDRExBM3UzOHAyM0s3VUhpTTBNcGE0WVJVS0Z3NWxXcXFzamc1M1BybjZEUlZLYjBPUlU2WlJEdUhYMXhOTUNLZldaa01uQkdLVkprR29MTkFHc01PeThGR2QzeW40bmY0TTlZMFBaZkd3azRKQW42VWV5Y05id2xyT0RITnJZXzdsUnBYNzJ0c1lSU2N0Yks5SG1CWS1TajQ0cmFjU3hoOFU?oc=5","date":"2026-02-06","type":"earnings","source":"Investor's Business Daily","summary":"This Pharma Stock With Earnings Seen Soaring 1,854% Forms Bullish Base - Investor's Business Daily","headline":"This Pharma Stock With Earnings Seen Soaring 1,854% Forms Bullish Base - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNZ0JFZFBCVElKc0w2LTd2VWJuMXk4YmN2aVU1TDBHUUxIOUNYU0U1ZmJiQUF6TjRoRUZvRm02aVVQaGt5Ti1IOHBtWWtzNUZ1SGlfSGFpbXVzSFVUNmxwMVBTUG1yVGM3QlRKVk9IODZ4eGFCR1pPMjdhMHlmel90XzEtanItSU5rNEJLeU1mQzZrZ25pODN4UnBQTGY1TF9Ha1QyLXdCcFFSbFRBS3h1aGU0QXZKekFvRzc4MU9fVnZUcmFna0Q5a21xNDhyQ3R6X2ZJOHBXSVlxRmY2MlE?oc=5","date":"2025-11-03","type":"regulatory","source":"Stocktwits","summary":"FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’ - Stocktwits","headline":"FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulati","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNUUtnMWd3ZlItTWlPSUV3NXFET2x5QzE2NE9WRUJ3R3BwajhBWjRFaWl2bDlqMEcxTGdUZWJnSlZnaWFMZF9tZ3h0cTZSMlZKQlo0Z0VBSkprV2NubFdfMWZ6Z0FOLXFDdDV0elBoVzJzdFc0YWdKOHROczlGYzMxYWlvMy1NOW51alRKZnVUQXJ5RXNlN1N6dkN4cVBZMEFidEJ2MXI0S0FEdXpu?oc=5","date":"2025-11-02","type":"regulatory","source":"Seeking Alpha","summary":"Top FDA official Tidmarsh resigns after comments on kidney drug, HHS probe - Seeking Alpha","headline":"Top FDA official Tidmarsh resigns after comments on kidney drug, HHS probe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOX3ZCbFVseWlDTG1rRTFUZ0pzNFFoXzhUNlJMdV9PWFhyRHRGUHpPTkxqQnVrRFdhTFVHZHpIRms5dzhCZ0ZTUXlfSmZDTURybTlqTjEtQzRBMlVLenVMZk94WVNtanE2ZUFWSkJUMHJ4SGZHZDl0ekxIV2tfc092dVB4MXk5MnplZjEwdU1mdEg2LTNQdU9YTzdNRlRZZ2JaNlliVk9QSQ?oc=5","date":"2025-09-29","type":"regulatory","source":"Sherwood News","summary":"Pharma company Aurinia falls after FDA official uses LinkedIn to call out lupus drug - Sherwood News","headline":"Pharma company Aurinia falls after FDA official uses LinkedIn to call out lupus drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNcUw1Nm9rWGFQX0p2aHVpblhPZzFYTTlCeUdmcVNYUmtEUlRUME5vcVZoSzdjTU5HUlh2XzJCd2Rld1FaTjcyLVY0bk92S2ppRmkxRVFHamVVOXNjYzJpdWlsOWFTN0U5UnpBaUxneF9idlktRzdxazlKNW1hbEZ3aldBUFhSYXAyTHlKZnN0WnZObkUxdmlfUkVNSUYwZFlwRXVOLXp6Tml2YTFEWHc?oc=5","date":"2025-08-06","type":"pipeline","source":"Seeking Alpha","summary":"Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade) (NASDAQ:AUPH) - Seeking Alpha","headline":"Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade) (NASDAQ:AUPH)","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":283055000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":283055000,"period":"2025-12-31"},{"value":77114000,"period":"2025-12-31"},{"value":73468000,"period":"2025-09-30"},{"value":70008000,"period":"2025-06-30"},{"value":62465000,"period":"2025-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":32505000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":287202000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":751587000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}